X
[{"orgOrder":0,"company":"Vasopharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"vasopharm Completes Patient Enrollment for Phase III Traumatic Brain Injury Trial (NOSTRA)","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase III","country":"GERMANY","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Vasopharm"},{"orgOrder":0,"company":"Vasopharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vasopharm Announces Last Patient Last Visit in NOSTRA III Traumatic Brain Injury Clinical Trial","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase III","country":"GERMANY","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Vasopharm"},{"orgOrder":0,"company":"Vasopharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vasopharm GmbH Announces Brain Lactate Microdialysate Data from Post Hoc Analyses of Clinical Trials in Traumatic Brain Injury","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase III","country":"GERMANY","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Vasopharm"}]
Find Drugs for Trauma (Emergency, Injury, Surgery) in Phase III Clinical Development in GERMANY
Filters
Details:
VAS203 (ronopterin) significantly reduces lactate levels in brain microdialysate from TBI patients reflecting energetic stability and neuroprotection during the early vulnerable phase.
Lead Product(s):
Ronopterin
Therapeutic Area: Trauma (Emergency, Injury, Surgery)
Product Name: VAS203
Highest Development Status: Phase III
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
July 12, 2022
Details:
The NOSTRA trial (NO Synthase in TRAumatic Brain Injury) is a pivotal European trial assessing the efficacy and safety of Ronopterin (VAS203) for the treatment of moderately to severely injured closed head traumatic brain (TBI) injury patients.
Lead Product(s):
Ronopterin
Therapeutic Area: Trauma (Emergency, Injury, Surgery)
Product Name: VAS203
Highest Development Status: Phase III
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
July 01, 2020
Details:
NOSTRA III is a 220 patient Phase III clinical trial assessing efficacy and safety of Ronopternin (VAS203) for the treatment of moderately to severely injured closed head traumatic brain injuries.
Lead Product(s):
Ronopterin
Therapeutic Area: Trauma (Emergency, Injury, Surgery)
Product Name: VAS203
Highest Development Status: Phase III
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
January 29, 2020